The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2015 | Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLL
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of the North Shore-LIJ Cancer Institute, Lake Success, NY, summarises the results of a phase 1b trial that evaluated the safety and efficacy of the PI3Kδ inhibitor, idelalisib, in combination with chemoimmunotherapeutic agents for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL). Investigated combinations included idelalisib with rituximab; ofatumumab; bendamustine and rituximab; fludarabine; and chlorambucil.
